Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.48 |
| ▸ | AURKA | O14965 | 6/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 5/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | RUNX1 | Q01196 | 2/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13596386 | 0.88 | KDR (0.48) | KDRAURKAERBB2NPC1RAB9A | |
| SCHEMBL4782770 | 0.83 | KDR (0.69) | KDRAURKAERBB2NPC1RAB9A | |
| SCHEMBL4782775 | 0.83 | KDR (0.69) | KDRAURKAERBB2NPC1RAB9A | |
| SCHEMBL4781712 | 0.82 | KDR (0.68) | KDRAURKAERBB2NPC1RAB9A | |
| SCHEMBL13596389 | 0.82 | KDR (0.68) | KDRAURKAERBB2NPC1RAB9A | |
| SCHEMBL14223421 | 0.80 | KDR (0.59) | KDRAURKAERBB2NPC1RAB9A | |
| SCHEMBL13596385 | 0.78 | KDR (0.68) | KDRAURKAERBB2NPC1RAB9A | |
| SCHEMBL13596387 | 0.78 | KDR (0.71) | KDRAURKAERBB2NPC1RAB9A | |
| SCHEMBL13596383 | 0.77 | KDR (0.74) | KDRAURKAERBB2NPC1RAB9A | |
| SCHEMBL4413745 | 0.77 | KDR (0.74) | KDRAURKAERBB2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638518-B2 | Substituted pyrazole kinase inhibitors | JANSSEN PHARMACEUTICA (BE) | 2009-12-29 | — | — | US | disclosed |
| US-7638518-B2 | Substituted pyrazole kinase inhibitors | JANSSEN PHARMACEUTICA (BE) | 2009-12-29 | — | — | US | disclosed |
| US-20080153844-A1 | 3-(Benzimidazol-2-yl)pyrazole derivatives; inhibitors of ATP and protein kinase interactions; diabetes, rheumatoid arthritis, Crohn's disease, septic shock, cachexia, pancreatitis, Alzheimer's disease, Parkinson's disease; antimetastasis, anticarcinogenic, antitumor, antidepressant, antiallergen agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-26 | — | — | US | disclosed |
| US-20080153844-A1 | 3-(Benzimidazol-2-yl)pyrazole derivatives; inhibitors of ATP and protein kinase interactions; diabetes, rheumatoid arthritis, Crohn's disease, septic shock, cachexia, pancreatitis, Alzheimer's disease, Parkinson's disease; antimetastasis, anticarcinogenic, antitumor, antidepressant, antiallergen agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-26 | — | — | US | disclosed |
| WO-2008048502-A1 | SUBSTITUTED PYRAZOLE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153844-A1 | 3-(Benzimidazol-2-yl)pyrazole derivatives; inhibitors of ATP and protein kinase interactions; diabetes, rheumatoid arthritis, Crohn's disease, septic shock, cachexia, pancreatitis, Alzheimer's disease, Parkinson's disease; antimetastasis, anticarcinogenic, antitumor, antidepressant, antiallergen agents | ADK, ATP5ME, ATP5MK | KDR 4185/4885AURKA 237/4885ERBB2 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.